Alto Neuroscience, Inc. Increase (Decrease) in Other Receivables
Alto Neuroscience, Inc. (ANRO) reported Increase (Decrease) in Other Receivables of -$8.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2024-11-12
- Alto Neuroscience, Inc. increase (decrease) in other receivables for the quarter ending 2024-09-30 was $0.00.
- Alto Neuroscience, Inc. increase (decrease) in other receivables for the quarter ending 2024-06-30 was $0.00.
- Alto Neuroscience, Inc. increase (decrease) in other receivables for the quarter ending 2024-03-31 was -$8.00K, a 121.62% decline year-over-year.
- Alto Neuroscience, Inc. increase (decrease) in other receivables for the quarter ending 2023-09-30 was -$295.00K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | -$8.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$8.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$8.00K 10-Q · filed 2024-05-14 | ||
| 2023-09-30 | -$295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$362.00K derived: sum of 2 quarters · filed 2024-11-12 | -$325.00K 10-Q · filed 2024-11-12 |
| 2023-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$30.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $37.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |